| http://www.w3.org/ns/prov#value | - The firms say they will now carry out a detailed analysis of the trial???s efficacy and safety data. ???Bringing new and innovative cancer therapies to patients can be incredibly challenging, especially in difficult-to-treat cancers such as second-line NSCLC,??? admits Debasish Roychowdhury, svp and head of global oncology at sanofi-aventis.
|
